• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association

Posted on: Monday, 21 September 2009, 15:27 CDT

WOBURN, Mass., Sept. 21 /PRNewswire/ -- The Center for Business Intelligence (CBI) announced today that they will donate a portion of the proceeds from their Alzheimer's Drug Development Summit to the Alzheimer's Association. CBI will donate $100 for every registration completed this week, September 21-25, 2009, in recognition of World Alzheimer's Day.

World Alzheimer's Day joins Alzheimer's associations, globally, to raise awareness and encourage citizens to take action against the disease. CBI is committed to developing forums that unite industry thought leaders in the field of Alzheimer's research and drug development. "By putting together cutting-edge forums and supporting the Alzheimer's Association, we're proud to be doing our part on this very important day," said Michelle DeMunbrun, Program Manager at CBI. "Every little bit counts, and with all of our collective efforts, it's only a matter of time before we establish a cure for this devastating disease."

The annual Alzheimer's Summit, in its third year, will be chaired by Ronald Black, M.D., Assistant Vice President, Neuroscience, Wyeth. The conference will take place in Arlington, VA, on December 8-9, 2009. Day-two case study, "Addressing the Two Most Challenging Aspects of Alzheimer's Clinical Trials -- Accelerating Patient Recruitment and Reducing Drop-Out Rates" will be a highlight at this timely and pertinent event. In addition to five other case studies and an extended panel discussion, attendees will have multiple opportunities to network with industry colleagues.

Top neuroscience and drug development executives from companies such as Eisai, Alzheimer's Association, The Critical Path Institute, Elan Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Wyeth and The National Institute on Aging will explore how to:

• Examine targeting protein kinases and the unique challenges associated with CNS drug discovery
• Discuss whether disease modifying therapeutics can show symptomatic benefits
• Assess whether the AD drug candidates, to date, failed the clinical trials or the clinical trials failed the drugs
• Gain a better understanding of AB trafficking and the peripheral sink hypothesis
• Learn the potential role of MRI and PET imaging in biomarkers in facilitating Alzheimer's disease drug development
• Examine the implications of ADNI data for use of neuroimaging and fluid biomarkers in clinical trials for Alzheimer's disease
• Discuss the integration of a mobile clinical network into an Alzheimer's clinical trial to meet sponsor and investigator deliverables and objectives
  

The conference brings together key researchers and stakeholders to examine the latest symptomatic and disease modifying approaches for the clinical development of new AD therapies. For more information on the conference or to view the agenda, please visit http://www.cbinet.com/alzheimers.

About CBI:

A subsidiary of Advanstar Communications, The Center for Business Intelligence is dedicated to developing market-driven, unbiased conferences in the pharmaceutical, biotechnology, and medical device industries. For more information, please visit http://www.cbinet.com.

For additional information or media inquiries, please contact: Emily Forest, Marketing Manager, at 339-298-2156.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

SOURCE The Center for Business Intelligence

Source: PR Newswire

More News in this Category